ABIVAX Société Anonyme (0RA9.L)
EUR 7.35
(-0.34%)
EUR 7.35
(-0.34%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -3.43 EUR | -9.58% |
| 2022 | -3.13 EUR | -26.72% |
| 2021 | -2.47 EUR | 5.73% |
| 2020 | -2.62 EUR | -4.38% |
| 2019 | -2.51 EUR | -60.9% |
| 2018 | -1.56 EUR | -36.84% |
| 2017 | -1.14 EUR | 22.97% |
| 2016 | -1.48 EUR | 10.3% |
| 2015 | -1.65 EUR | -89.66% |
| 2014 | -1171.27 EUR | -35.94% |
| 2013 | -852.28 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -1.30 EUR | 0.0% |
| 2023 Q2 | -1.45 EUR | 0.0% |
| 2023 Q4 | -1.91 EUR | 0.0% |
| 2023 FY | - EUR | -9.58% |
| 2022 Q4 | -1.81 EUR | 0.0% |
| 2022 FY | - EUR | -26.72% |
| 2022 Q2 | -1.76 EUR | 0.0% |
| 2021 FY | - EUR | 5.73% |
| 2021 Q4 | -1.48 EUR | 0.0% |
| 2021 Q2 | -1.13 EUR | 0.0% |
| 2020 Q4 | -1.55 EUR | 0.0% |
| 2020 Q2 | -1.26 EUR | 0.0% |
| 2020 FY | - EUR | -4.38% |
| 2019 Q2 | -1.38 EUR | 0.0% |
| 2019 FY | - EUR | -60.9% |
| 2019 Q4 | -1.35 EUR | 0.0% |
| 2018 Q4 | -0.82 EUR | 0.0% |
| 2018 FY | - EUR | -36.84% |
| 2018 Q2 | -0.73 EUR | 0.0% |
| 2017 Q2 | -0.57 EUR | 0.0% |
| 2017 FY | - EUR | 22.97% |
| 2017 Q4 | -0.56 EUR | 0.0% |
| 2016 Q4 | -0.61 EUR | 0.0% |
| 2016 Q2 | -0.86 EUR | 0.0% |
| 2016 FY | - EUR | 10.3% |
| 2015 FY | - EUR | -89.66% |
| 2015 Q4 | -0.89 EUR | 0.0% |
| 2015 Q2 | -0.74 EUR | 0.0% |
| 2014 Q4 | -640.20 EUR | -199962.5% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | - EUR | -35.94% |
| 2014 Q3 | -0.32 EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Boiron SA | 2.06 EUR | 266.505% |
| Laboratorios Farmaceuticos Rovi, S.A. | 3.20 EUR | 207.188% |
| Vetoquinol SA | 4.70 EUR | 172.979% |
| Valneva SE | -0.73 EUR | -369.863% |
| AB Science S.A. | -0.20 EUR | -1615.0% |
| Nanobiotix S.A. | -1.08 EUR | -217.593% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 31.4% |
| Vivoryon Therapeutics N.V. | -1.12 EUR | -206.25% |
| BioSenic S.A. | -0.21 EUR | -1533.333% |
| Formycon AG | 4.76 EUR | 172.059% |